title: Clinical evaluation of the efficacy of an antithrombin agent "Argatroban" combined with exercise therapy on increase of the skeletal muscle blood flow.
abstract: Argatroban has selective antithrombin activity and widely used for treatment of ASO. In this study we investigated vasodilating activity of Argatroban besides antithrombin activity in ASO patients. Three patients who have undergone F-P bypasses previously which were all occluded received 10 mg or 20 mg of Argatroban per day intravenously for 4 weeks. Skin temperature were measured before and after administration of Argatroban at the point of 1, 2, 4 weeks which increased 2.3-6.0 degrees C after administration of Argatroban. Subjective symptoms were also improved and these patients became to be able to walk 1.5-3.3 km. These patients were also given PGE, intravenously, however, temperature increase was less than 1.1 degrees C. These results showed that Argatroban has not only antithrombin activity but also significant vasodilating activity resulting in increase of skeletal muscle blood flow.
authors.affiliation: Department of Cardiovascular Surgery, Kyoto Mitsubishi Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Murata
authors.forename: A
authors.initials: A
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Nakajima
authors.forename: A
authors.initials: A
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Kurosawa
authors.forename: S
authors.initials: S
authors.lastname: Miki
authors.forename: T
authors.initials: T
authors.lastname: Mizoguchi
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: A
authors.initials: A
authors.lastname: Kawatani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000008:administration & dosage*; D001120:Arginine / Q000031:analogs & derivatives; D001162:Arteriosclerosis Obliterans / Q000503:physiopathology / Q000628:therapy*; D019917:Blood Vessel Prosthesis Implantation; D003131:Combined Modality Therapy; D005081:Exercise Therapy; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000098:blood supply*; D010875:Pipecolic Acids / Q000008:administration & dosage*; D011458:Prostaglandins E / Q000008:administration & dosage; D012008:Recurrence; D012039:Regional Blood Flow; D012881:Skin Temperature; D013449:Sulfonamides; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D000991:Antithrombins; D010875:Pipecolic Acids; D011458:Prostaglandins E; D013449:Sulfonamides; D014665:Vasodilator Agents; D001120:Arginine; C031942:argatroban